Early data from a phase I study of tafasitamab in CLL indicated that tafasitamab does not induce a loss of CD19 expression[25], but this remains to be further investigated to understand the mechanism of resistance as well as how to sequence this therapy with CD19-directed CAR-T therapy. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.